Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review
DOI:
https://doi.org/10.15584/ejcem.2024.1.5Keywords:
docosahexaenoic acid, eicosapentaenoic acid, omega-3 polyunsaturated fatty acids, schizophrenia, supplementationAbstract
Introduction and aim. In patients with schizophrenia, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) treatment was found to ameliorate the cardiovascular, metabolic, and inflammatory problems caused by antipsychotic medication and even reduce the need for medication by 20%. In this study, we evaluated the potential therapeutic effects of n-3 PUFA supplementation in patients with schizophrenia.
Material and methods. The PRISMA guidelines were followed in conducting this systematic review. The Embase, MEDLINE, Web of Science, and Google Scholar databases were searched electronically. The first search yielded 50 papers in total. Subse quently, 43 publications that did not meet our eligibility requirements were removed, and seven articles were selected.
Analysis of the literature. The analysis showed that n-3 PUFA supplementation and the placebo group both decreased their psychotic (PANSS and GAF scales) and Calgary Depression Scale symptomatology and boosted their functional ability (GAF) when used as an adjuvant to antipsychotic medication. When administered as a monotherapy with a metabolic antioxidant, n-3 PUFA supplementation proved beneficial for treating schizophrenia. In patients with schizophrenia, n-3 PUFAs have thera peutic benefits as adjuvant treatments to medications, although not for different variables or patient groups.
Conclusion. In many studies, patients with chronic schizophrenia who received n-3 PUFA supplementation showed no improvement in their clinical condition.
Downloads
References
Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067. doi: 10.1038/nrdp.2015.67
Fatouros-Bergman H, Cervenka S, Flyckt L. Meta-analysis of cognitive performance in drug-naive patients with schizophrenia. Schizophr Res. 2014;158:156-162. doi: 10.1016/j.schres.2014.06.034
Tsuang M. Schizophrenia: genes and environment. Biol Psychiatr. 2000;47:210-220. doi: 10.1016/s0006-3223(99)00289-9
Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatr. 2003;60(12):1187-1192. doi: 10.1001/archpsyc.60.12.1187
Freedman R, Leonard S, Olincy A, et al. Evidence for the multigenic inheritance of schizophrenia. Am J Med Genet. 2001;105(8):794-800. doi: 10.1002/ajmg.10100
Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives fromstructural neuroimaging studies. Schizophr Bull. 2011;37(3):504-513. doi: 10.1093/schbul/sbr030
Kidd PM. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. Altern Med Rev. 2007;12(3):207-227.
Uauy R, Peirano P, Hoffman D, Mena P, Birch D, Birch E. Role of essential fatty acids in the function of the developing nervous system. Lipids. 1996;31(1):167-176. doi: 10.1007/BF02637071
Miyoshi T, Noda Y, Ohno Y, et al. Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals - a randomized cross-over trial. Biomed Pharmacother. 2014;68(8):1071-1077. doi: 10.1016/j.biopha.2014.10.008
Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115. doi: 10.1042/BST20160474
Berger GE, Proffitt T-M, McConchie M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J Clin Psychiatry. 2007;68(12):1867-1875. doi: 10.4088/jcp.v68n1206
Amminger GP, Schäfer MR, Papageorgiou K, et al. Long-Chain ω-3 Fatty Acids for Indicated Prevention of Psychotic Disorders. Arch Gen Psychiatry. 2010;67(2):146. doi: 10.1001/archgenpsychiatry.2009.192.
Urrútia G, Bonfill X. PRISMA declaration: a proposal to improve the publication of systematic reviews and meta-analyses. Med Clin (Barc). 2010;135(11):507-511. doi: 10.1016/j.medcli.2010.01.015
Qiao Y, Mei Y, Han H, et al. Effects of Omega-3 in the treatment of violent schizophrenia patients. Schizophr Res. 2018;195:283-285. doi: 10.1016/j.schres.2017.08.026
Robinson DG, Gallego JA, John M, et al. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res. 2019;204:295-303. doi: 10.1016/j.schres.2018.09.006
Jamilian H, Solhi H, Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob J Health Sci. 2014;6(7):103-108. doi: 10.5539/gjhs.v6n7p103
Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016;73:34-44. doi: 10.1016/j.jpsychires.2015.11.013
Emsley R, Chiliza B, Asmal L, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014;158(1-3):230-235. doi: 10.1016/j.schres.2014.06.004
Satogami K, Takahashi S, Yamada S, Ukai S, Shinosaki K. Omega-3 fatty acids related to cognitive impairment in patients with schizophrenia. Schizophr Res Cogn. 201718;9:8-12. doi: 10.1016/j.scog.2017.05.001
Behdani F, Roudbaraki SN, Saberi-Karimian M, et al. Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate. Psychiatry Res. 2018;261:243-247. doi: 10.1016/j.psychres.2017.12.028
Xu F, Fan W, Wang W, et al. Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial. Psychopharmacology (Berl). 2019;236(4):1273-1279. doi: 10.1007/s00213-018-5136-9
Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359-368. doi: 10.2147/CLEP.S66677
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments. BMC Med Res Methodol. 2014;14:45. doi: 10.1186/1471-2288-14-45
Amminger GP, Mechelli A, Rice S, et al. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Transl Psychiatry. 2015;5(1):e495. doi: 10.1038/tp.2014.134
Bentsen H, Solberg DK, Refsum H, et al. Clinical and biochemi cal validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells. Prostaglan dins Leukot Essent Fatty Acids. 2012;87(1):35-41. doi: 10.1016/j.plefa.2012.05.005
Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res. 2001;49(3):243-251. doi: 10.1016/s0920-9964(00)00083-9
Horrobin DF, Jenkins K, Bennett CN, et al. Eicosapentaenoic acid and arachidonic acid: Collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids. 2002;66(1):83-90. doi: 10.1054/plef.2001.0338
van Erp TGM, Preda A, Nguyen D, et al. Converting positive and negative symptom scores between PANSS and SAPS/SANS. Schizophr Res. 2014;152(1):289-294. doi: 10.1016/j.schres.2013.11.013
Misiak B, Stanczykiewicz B, Laczmanski L, et al. Lipid pro file disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis. Schizophr Res. 2017;190:18-27. doi: 10.1016/j.schres.2017.03.031
Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients. 2010;2(3):355-374. doi: 10.3390/nu2030355
Su KP. Biological mechanism of antidepressant effect of omega-3 fatty acids: How does fish oil act as a ‘mind-body interface’? Neuro signals. 2009;17(2):144-152. doi: 10.1159/000198167
Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: A systematic review. J Psychiatric Res. 2013;47(2):197-207. doi: 10.1016/j.jpsychires.2012.10.005
Zheng P, Zeng B, Liu M, et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci Adv. 2019;5(2):eaau8317. doi: 10.1126/sciadv.aau8317
Cuomo A, Maina G, Rosso G, et al. The microbiome: a new target for research and treatment of Schizophrenia and its resistant presentations? A systematic literature search and review. Front Pharmacol. 2018;9:1040. doi: 10.3389/fphar.2018.01040
Costantini L, Molinari R, Farinon B, Merendino N. Impact of Omega-3 Fatty Acids on the Gut Microbiota. Int J Mol Sci. 2017;18:2645. doi: 10.3390/ijms18122645
Hakimian JK, Dong TS, Barahona JA, et al. Dietary Supplementation with Omega-3 Polyunsaturated Fatty Acids Reduces Opioid-Seeking Behaviors and Alters the Gut Microbiome. Nutrients. 2019;11(8):1900. doi: 10.3390/nu11081900
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
